YARW Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potenti
YARW Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye Disease
Story updates
11:08:17 AM UTC
SquawkNews
Yarrow Bioscience...
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.